ClinicalTrials.gg
Not yet recruitingNCT05504031HYCORE1Updated Jun 3, 2026

The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting

An interventional study of Hybrid coronary revascularization and Conventional revascularization in Coronary Artery Disease, sponsored by Rigshospitalet, Denmark. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,048
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark — 5 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Rigshospitalet, Denmark.

Planned enrollment
5th of 15
1,048 · median 331
Started
2026
the only one that year
No phase
14 of 18
5 open now
Registered
15th of 18
by date

Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 14 with no phase, and was the 15th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

Coronary artery disease often necessitates complex interventions like coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) with stents. Hybrid coronary revascularization, a minimally invasive approach, integrates both methods for complete revascularization. This multicenter randomized trial involves 1200 patients, comparing hybrid coronary revascularization to CABG in a 1:1 ratio. Eligible participants have multi-vessel coronary disease and are referred for elective or sub-acute CABG. Inclusion criteria include age 18 or older, significant multi-vessel disease, and potential complete revascularization with both methods. Exclusion criteria include chronic kidney disease, pregnancy, contradiction to dual antiplatelet therapy, recent myocardial infarction, and acute revascularization. The hybrid group undergoes staged revascularization, combining minimally invasive grafting of the left interior mammary artery to the left anterior descending artery with PCI-stenting of remaining lesions. The control group undergoes conventional CABG with sternotomy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, or unplanned hospitalization, while secondary outcomes include periprocedural complications, cardiovascular mortality, hospital-free days within 90 days, angina frequency, and quality of life. Evaluation occurs 12 months after randomization. The trial commences in 2024, with inclusion expected to conclude in 5 years.

Read the detailed description

Background Cardiovascular diseases, mainly coronary artery disease (CAD), are the leading causes of death worldwide. CAD is characterised by the narrowing or blockage of blood flow in the coronary arteries often necessitating complex interventions like coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with drug-eluting stents. The preferred revascularisation strategy depends on several characteristics, one being the number of diseased vessels. Multi-vessel coronary artery disease (MVD) is defined as stenosis of at least two major coronary arteries.

Over the years, several large trials have concluded that CABG and PCI with newer-generation drug-eluting stents are both associated with improved survival rates compared to medical therapy.

CABG is still regarded as the gold standard for complex multi-vessel disease, with the cornerstone being the in-situ left internal mammary artery (LIMA) anastomosed to the left anterior descending artery (LAD).1 Current guidelines recommend CABG or PCI with equipoise in patients with one-vessel proximal LAD stenosis, two-vessel disease with proximal LAD stenosis, left main disease or three-vessel disease with lower complexity. The LIMA graft, with its excellent patency, has been shown to outperform PCI of the LAD and is in part responsible for the apparent success and survival benefit of CABG.3 However, saphenous vein grafts, the most common graft for non-LAD targets perform rather poorly, with graft failure ranging as high as 43%, 18 months after surgery. PCI with DES, especially with intravascular imaging, is documenting meagre failure rates and may consequently offer better results in non-LAD vessels than CABG with vein grafts does.

Despite its survival benefits, the CABG comes at the cost of a full sternotomy, necessitating longer rehabilitation. Patients may prefer less invasive treatment options if these are feasible and have consistent long-term results. The minimally invasive coronary artery bypass (MIDCAB) procedure was developed as a less invasive method for revascularisation. MIDCAB allows for the grafting of the anterior vessels through a small left anterior thoracotomy without the use of extracorporeal circulation. Thus, ensuring vital revascularisation with a lesser trauma.

Complete revascularisation has been established as the most important factor for survival. Recent data have showed comparable 10-year mortality in patients achieving this goal with either PCI or CABG.

Hybrid coronary revascularisation was developed to combine the best parts of the two revascularisation techniques, consisting of a minimally invasive grafting of the LIMA to LAD, and PCI of all functionally significant non-LAD stenoses. Theoretically, patients may obtain the survival benefit from the LIMA-LAD graft, from a less invasive approach and avoidance of vein graft failures.

However, to this date, hybrid coronary revascularisation is supported by very limited data. Only three small, randomised feasibility trials have been conducted, which all stated that the procedure is feasible but that larger randomised trials are necessary to determine if it is a suitable alternative to treating multi-vessel disease.

Trial objective The trial objective is to assess the beneficial and harmful effects of hybrid coronary revascularisation versus CABG in patients with multi-vessel coronary artery disease.

Trial design The trial investigators will conduct a multicentre randomised superiority trial comparing hybrid coronary revascularisation versus conventional CABG surgery in patients with multi-vessel coronary artery disease.

Patients will be randomised 1:1 to hybrid coronary revascularisation or CABG. The randomisation will be stratified according to clinical site and diabetes (yes/no).

Selection of participants All patients with multi-vessel coronary disease referred for a CABG will be discussed during the Heart Team Conference and considered for participation in the trial.

Inclusion criteria

  • Written informed consent
  • ≥ 18 years of age
  • Functionally significant MVD, defined as ≥ 70% diameter stenosis by visual estimation or functionally significant stenosis (FFR \< 0.80, non-hyperaemic index (iFR) \< 0.89) in at least two of the major epicardial vessels or major side branches
  • Patient history reviewed by both cardiac surgeon and cardiologist who in agreement find both CABG and hybrid revascularisation indicated and technically feasible with an expectation of complete revascularisation of all functionally significant stenoses in the LAD and at least one other coronary artery ≥ 2.5mm in diameter or left main bifurcation stenosis with functionally significant stenoses in both the LAD and left circumflex artery.

Exclusion criteria

  • Chronic kidney disease with estimated glomerular filtration rate \< 20 mL/min/kg
  • Pregnancy
  • Contraindications to the use of dual antiplatelet therapy
  • STEMI within 1 month
  • Indication for acute revascularization

Trial intervention

Experimental intervention:

Coronary revascularisation will be conducted as a staged intervention. First, the MIDCAB will be conducted through a small left anterior thoracotomy, with endoscopic LIMA harvest and off-pump LIMA to LAD-grafting. Second, PCI with implantation of contemporary DES of all non-LAD lesions will be conducted within 4 weeks of the surgical procedure. Patients will receive dual antiplatelet therapy (DAPT) according to local routine and international guidelines.

A "reverse hybrid" with PCI preceding MIDCAB is also an option in patients with sub-acute coronary syndrome or CTO. Surgery will be conducted 3 months after PCI when it is safe to pause DAPT. PCI of CTO, guided by viability tests, may further be staged at up to 30 days after MIDCAB surgery.

Control intervention:

Coronary revascularisation will be conducted as a conventional CABG, through a sternotomy, on- or off-pump with grafting of all target vessels, according to local best practice. All graft types are permitted and, therefore, surgeons decide their own specific graft strategy.

CABG, MIDCAB, and PCI are all standard procedures performed routinely at the hospitals. Therefore, there is no expected increased risk for trial participants no matter which group they are randomized to.

The statistical analysis will adhere to the intention-to-treat principle, meaning that participants will be analyzed based on their originally assigned groups even if they undergo a crossover to other interventions.

Outcome measures

Primary outcome:

  • A composite outcome of either all-cause mortality, a diagnosis of myocardial infarction, a diagnosis of stroke, or any unplanned hospitalization at 12 months postoperatively.

Secondary outcomes:

  • Periprocedural complications defined as periprocedural myocardial infarction, stroke, unplanned re-intervention, BARC 3-5 bleeding complications10, or surgical wound infection.
  • Cardiovascular mortality
  • Hospital free days within 90 days after randomization
  • Angina frequency using the Seattle Angina Questionnaire11
  • Health-related quality of life using EQ-5D12

Exploratory outcomes:

  • Serious adverse events (dichotomous). We will use the International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use-Good Clinical Practice (ICH-GCP) definition of a serious adverse event, which is any untoward medical occurrence that resulted in death, was life-threatening, required hospitalisation or prolonging of existing hospitalisation and resulted in persistent or significant disability or jeopardised the participant.
  • Major Adverse Kidney Events to 30 days (MAKE30), defined as either death, new renal replacement therapy, or persistent renal dysfunction (creatinine at discharge or day 30 ≥ 200% of the baseline serum creatinine value)
  • Post-pericardiotomy syndrome (diagnosed by two of the following being present: fever without alternative cause, pleuritic chest pain, friction rub on auscultation and evidence of new or worsening pericardial or pleural effusion)
  • Postoperative pain
  • Procedure related reoperation
  • Prolonged intubation (> 48 hours)
  • Acute kidney injury within 48 hours, defined by the KDIGO criteria
  • Biomarkers during hospital stay
  • Length of stay
  • Urgent revascularisation or myocardial infarction
  • Admission for new onset of heart failure
  • Completeness of index revascularisation
  • Target vessel failure
  • Target vessel revascularisation
  • Any repeat revascularisation
  • Definite stent thrombosis
  • Atrial fibrillation (AF) within 3 months of revascularisation
  • Sternal wound infections - superficial and deep
  • Sternal wound dehiscence
  • New York Heart Association (NYHA) class
  • Healthcare costs
  • Major arrhythmia within 30 days
  • Graft failure assessed on cardiac computed tomography (CT) at 1 year (if the procedure is conducted)

Sample size and power estimation Provided that the incidence of all-cause mortality, a diagnosis of myocardial infarction, a diagnosis of stroke, or hospitalization in the control group is equal to 55%, an absolute risk reduction of 10% (corresponding to a relative risk reduction of 18.2%), α=0.05, beta=0.10 (giving a power of 90%) we will need 524 participants in the intervention and in the control group. Notably, a 10% absolute risk reduction corresponds to an incidence of either all-cause mortality, a diagnosis of myocardial infarction, a diagnosis of stroke, or hospitalization equal to 45% in the experimental intervention group.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • Hybrid coronary revascularization
  • PCI
  • CABG
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • ≥ 18 years of age
  • Functionally significant MVD, defined as ≥ 70% diameter stenosis by visual estimation or functionally significant stenosis (FFR \< 0.80, non-hyperaemic index (iFR) \< 0.89) in at least two of the major epicardial vessels or major side branches
  • Patient history reviewed by both cardiac surgeon and cardiologist who in agreement find both CABG and hybrid revascularisation indicated and technically feasible with an expectation of complete revascularisation of all functionally significant stenoses in the LAD and at least one other coronary artery ≥ 2.5mm in diameter or left main bifurcation stenosis with functionally significant stenoses in both the LAD and left circumflex artery.

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease with estimated \< 20 mL/min/kg
  • Pregnancy
  • Left main stenosis without additional functionally significant stenoses in both the LAD and the LCX
  • to the use of dual antiplatelet therapy
  • STEMI within 1 month
  • Indication for acute revascularization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,048 participants (estimated)

Study arms

  • Experimental
    Hybrid Group

    Complete revascularisation through a combined MIDCAB (LIMA-LAD graft trough a minimal invasive left anterior thoracotomy) and PCI (of all non-LAD stenoses)

    Procedure: Hybrid coronary revascularization

  • Active comparator
    CABG Group

    Conventional CABG through a sternotomy

    Procedure: Conventional revascularization

Interventions

  • ProcedureHybrid coronary revascularization

    Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)

  • ProcedureConventional revascularization

    Conventional revascularization with CABG of all significant stenoses through a sternotomy

06

What researchers measure

Primary outcomes

  1. A composite outcome of either all-cause mortality, a diagnosis of spontaneous myocardial infarction, a diagnosis of stroke, or any unplanned hospitalization

    A composite outcome of either all-cause mortality, a diagnosis of spontaneous myocardial infarction, a diagnosis of stroke, or any unplanned hospitalization

    Time frame: 12 months after randomization

Secondary outcomes

  1. Angina symptoms

    Angina symptoms measured using Seattle Angina Questionnaire

    Time frame: 12 months after randomization

  2. Health related quality of life

    Health related quality of life using EQ-5D

    Time frame: 12 months after randomization

  3. Hospital free days

    Hospital free days

    Time frame: 90 days after randomization

  4. Procedural complications

    Procedural complications defined as periprocedural myocardial infarction, unplanned re-intervention, stroke, BARC 3-5 bleeding complications or sternal wound infection

    Time frame: 12 months after randomization

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Yes — We plan to make all data publicly available in peer-review papers, after the trial has been finalized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: At the end of the trial

Access criteria: In peer-review papers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2030, 42 months later.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 42 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Aug 17, 2022
StartEst.
Jul 15, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2044
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05504031
Collaborators
Copenhagen Trial Unit, Center for Clinical Intervention Research, UMC Utrecht, Universitaire Ziekenhuizen KU Leuven
Responsible party
Christian Lildal Carranza (Chief Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Aug 17, 2022
Start date
Jul 15, 2026 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2044 (estimated)
Last update
Jun 3, 2026

Study contacts

Erika Nodin, MD
Contact
enod0001@regionh.dk
004535451172
Christian Carranza, MD, E-MBA
study director · Department of Cardiothoracic Surgery, Copenhagen University Hospital, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion